Clinical trial
A Phase 1b Randomized, Double-Blind, Placebo Controlled, Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (Inhaled Dry Powder Cannabidiol [CBD]) in a Clinical Model of Photosensitive Epilepsy
NCT05678881 is registered in ClinicalTrials.gov with Receptor Life Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Randomized, Double-Blind, Placebo Controlled, Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (Inhaled Dry Powder Cannabidiol [CBD]) in a Clinical Model of Photosensitive Epilepsy
- Lead sponsor
- Receptor Life Sciences
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- April 25, 2022
- Completion date
- February 23, 2024
- Enrollment
- 2 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.